Loading [MathJax]/jax/output/SVG/jax.js
Research article Topical Sections

Impact of photovoltaic grid-tied systems on national grid power factor in Palestine

  • Residential photovoltaic systems are a cost-effective solution for Palestinians to reduce their power costs while improving the environment. Despite their numerous advantages, these systems have several negative effects on the entire electric grid infrastructure. Increased penetration of photovoltaic (PV) systems, for example, may result in a fall in the power factor of the distribution grid. When the power factor is low, heat production and switch failures are more likely to occur. Even though comparable research has been published in the past, this is the first time PV systems have been investigated in terms of power factors in Palestine. This research serves as a resource for people interested in how photovoltaics (PVs) impact their systems' total power factor. To begin, the researchers in this study presented an intuitive power factor selection criterion for photovoltaic (PV) systems. Second, the article included a proposal for an auxiliary power factor controller. This article's conclusions may be utilized by municipalities, grid operators, and legislators to aid them in planning, forecasting, and accommodating new PV systems in their grids in terms of total power factor, as demonstrated by the results of this study. However, even though the data in this study is drawn from Palestinian sources, it may be applied to other regions because the data sets used are worldwide in scope.

    Citation: Amer Braik, Asaad Makhalfih, Ag Sufiyan Abd Hamid, Kamaruzzaman Sopian, Adnan Ibrahim. Impact of photovoltaic grid-tied systems on national grid power factor in Palestine[J]. AIMS Energy, 2022, 10(2): 236-253. doi: 10.3934/energy.2022013

    Related Papers:

    [1] Rahat Zarin, Abdur Raouf, Amir Khan, Aeshah A. Raezah, Usa Wannasingha Humphries . Computational modeling of financial crime population dynamics under different fractional operators. AIMS Mathematics, 2023, 8(9): 20755-20789. doi: 10.3934/math.20231058
    [2] Hasib Khan, Jehad Alzabut, J.F. Gómez-Aguilar, Praveen Agarwal . Piecewise mABC fractional derivative with an application. AIMS Mathematics, 2023, 8(10): 24345-24366. doi: 10.3934/math.20231241
    [3] E. Bonyah, C. W. Chukwu, M. L. Juga, Fatmawati . Modeling fractional-order dynamics of Syphilis via Mittag-Leffler law. AIMS Mathematics, 2021, 6(8): 8367-8389. doi: 10.3934/math.2021485
    [4] Shakeel Muhammad, Obaid J. Algahtani, Sayed Saifullah, Amir Ali . Theoretical and numerical aspects of the Malaria transmission model with piecewise technique. AIMS Mathematics, 2023, 8(12): 28353-28375. doi: 10.3934/math.20231451
    [5] Ateq Alsaadi . Advancing water quality management: A synergistic approach using fractional differential equations and neural networks. AIMS Mathematics, 2025, 10(3): 5332-5352. doi: 10.3934/math.2025246
    [6] Muhammad Rifqy Adha Nurdiansyah, Kasbawati, Syamsuddin Toaha . Stability analysis and numerical simulation of rabies spread model with delay effects. AIMS Mathematics, 2024, 9(2): 3399-3425. doi: 10.3934/math.2024167
    [7] Najat Almutairi, Sayed Saber . Chaos control and numerical solution of time-varying fractional Newton-Leipnik system using fractional Atangana-Baleanu derivatives. AIMS Mathematics, 2023, 8(11): 25863-25887. doi: 10.3934/math.20231319
    [8] Sabri T. M. Thabet, Reem M. Alraimy, Imed Kedim, Aiman Mukheimer, Thabet Abdeljawad . Exploring the solutions of a financial bubble model via a new fractional derivative. AIMS Mathematics, 2025, 10(4): 8587-8614. doi: 10.3934/math.2025394
    [9] Bahar Acay, Ramazan Ozarslan, Erdal Bas . Fractional physical models based on falling body problem. AIMS Mathematics, 2020, 5(3): 2608-2628. doi: 10.3934/math.2020170
    [10] Saima Rashid, Fahd Jarad, Fatimah S. Bayones . On new computations of the fractional epidemic childhood disease model pertaining to the generalized fractional derivative with nonsingular kernel. AIMS Mathematics, 2022, 7(3): 4552-4573. doi: 10.3934/math.2022254
  • Residential photovoltaic systems are a cost-effective solution for Palestinians to reduce their power costs while improving the environment. Despite their numerous advantages, these systems have several negative effects on the entire electric grid infrastructure. Increased penetration of photovoltaic (PV) systems, for example, may result in a fall in the power factor of the distribution grid. When the power factor is low, heat production and switch failures are more likely to occur. Even though comparable research has been published in the past, this is the first time PV systems have been investigated in terms of power factors in Palestine. This research serves as a resource for people interested in how photovoltaics (PVs) impact their systems' total power factor. To begin, the researchers in this study presented an intuitive power factor selection criterion for photovoltaic (PV) systems. Second, the article included a proposal for an auxiliary power factor controller. This article's conclusions may be utilized by municipalities, grid operators, and legislators to aid them in planning, forecasting, and accommodating new PV systems in their grids in terms of total power factor, as demonstrated by the results of this study. However, even though the data in this study is drawn from Palestinian sources, it may be applied to other regions because the data sets used are worldwide in scope.



    Breast cancer is the second leading cause of cancer death for women worldwide [1,2]. Approximately 75% of breast cancer cases are estrogen receptor positive [3]. The MCF-7 cell line is a common in vitro model used for studies on human breast cancer. The popularity of MCF-7 can be attributed to its estrogen responsiveness through expression of estrogen receptor, making it an idea model to study the effect of hormones on cell proliferation and protein synthesis [4,5,6].

    White blood cells are the cells of the immune system that helps the body fight infectious disease and foreign invaders. All WBCs are produced in the bone marrow and found in the blood and lymphatic system [7]. The number of WBCs in the blood is often a marker of disease. A low WBC count may occur as a result of viral infections, cancer treatment, bone marrow condition, or certain diseases [8]. An individual with a low WBC count may increase frequency of infections and fevers and cause low immunity [9]. Shankar et al. [10] have found an association between WBC count and cancer mortality. Other clinical studies have reported that there is no significant association between WBC count and cancer risk or cancer mortality [11,12,13,14].

    Natural killer cells are specialized WBCs and form a very important component of the innate system. They are able to detect early-stage developing tumors and secrete immuno-regulatory cytokines and numerous chemokines that directly and effectively eliminate tumor cells. This process is sometimes called immune surveillance, and it is an important process to prevent neoplastic cells from developing into tumors. Cytotoxic T lymphocytes, which are produced in the bone marrow and migrate to the thymus for maturation, are key players of adaptive immune system. Upon activation of CTLs, the T-cell antigen receptors expressed on CTLs allow them to monitor all cells of the body, ready to destroy infected cells. Cytotoxicity is mediated through Fas or perforin pathways inducing apoptosis in target cells [15].

    Despite the antitumor effect of NK cells and CTLs, there are still neoplastic cells that escape immune surveillance. However, even a fast growing tumor cannot grow beyond 1-2 mm in diameter without angiogenesis. At this stage, a balance exists between cell proliferation and apoptosis, and tumors may maintain dormant for years. Furthermore, clinical evidence has suggested that many of us have microscopic tumors that remain asymptomatic and never develop and progress to become large and lethal [16,17,18]. In fact, it has been estimated that more than one third of middle aged women who have never been diagnosed with breast cancer throughout their life were found at autopsy with in situ tumors in their breast [16]. When tumors develop their own vascularization, they can grow much larger and become lethal.

    Mathematical modeling of tumor growth is a powerful tool to understand, predict, and improve the outcome of a treatment regimen. A mathematical model of tumor growth often includes tumor-immune interaction which is an important component for the model to produce clinical phenomena. Most mathematical models for cancer are based on differential equations [19]. While partial differential equations have been employed to model the spatio-temporal growth and spread of cancer cells, ordinary differential equations (ODEs) have been used to investigate the interactions among cancer cells, immune cells, and cytokines [20]. ODE systems with two or three cell populations, which usually contain tumor cells and effector cells, have been constructed to study the population dynamics [21,22,23,24,25,26,27,28,29,30]. These models are able to capture the essential patterns of tumor growth and decay: exponential/oscillatory growth or decay of tumor cells. Forys et al. [30] and de Vladar and Gonzˊalez [29] have reported the existence of stable small tumor equilibria in their models. These dynamics can describe dormant or persistent microscopic tumors. However these results are merely obtained by mathematical models [29,30] while the interaction terms and parameter values in the mathematical models have not been verified by experimental or clinical data.

    More complex models involving more equations are devised to study particular aspects of tumor biology and have been able to provide significant insights into the mechanisms of tumor-immune interactions. These models inevitably involve more parameters and thus less well parameterized [20]. de Boer et al. [31] have considered an ODE system of eleven equations and reported that the cytotoxic T lymphocyte (CTL) count depends on the time of T helper cell activation. They have also pointed out that a tumor with strong antigenicity is destroyed by CD8+ T cells while a tumor with weak antigenicity is destroyed by macrophages. Numerical simulation using an ODE system of six equations by Cappuccio et al. [32] has suggested that IL-21 can be used to treat non-immunogenic tumors but not highly immunogenic tumors. Kronik st al. [33] have proposed a model, which includes gliomas cancer cells, CTLs, MHC class Ⅰ and Ⅱ molecules, and two cytokines, to study the effects of immunotherapy.

    Jarrett et al. [34] have proposed a mathematical model of HER2+ breast cancer with immune response and studied the outcomes of trastuzumab treatment. Annan et al. [35] have constructed an ODE system describing the interactions between breast cancer cells and immune cells including CTLs, macrophages, NK cells, and helper T cells. Roe et al. [36] have presented a mathematical model to study the effect of chemotherapy on breast cancer. Most of the parameter values and the functional forms in these studies have not been justified by experimental and clinical data. The purpose of this paper is to build a mathematical model using ODEs which describe MCF-7 breast tumor growth, tumor-immune interaction, and tumor-estrogen interaction. Experimental data from several research studies are used to determine the functional responses and parameter values in the mathematical model. The dynamics produced by the mathematical model are to be compared with experimental and clinical phenomena. To provide details, the mathematical model is presented in Section 2. Numerical examples and discussion are given in Section 3. Finally, a brief conclusion is made in Section 4.

    The model considered in this paper consists of five state variables: the MCF-7 tumor population T (cells), the circulating level of estradiol E (pmol/L), NK cell population N (cells/L), CTL (or CD8+ T) cell population L (cells/L), and WBC population C (cells/L). The mathematical model is described as the following ODEs:

    dTdt=(a+ITE(T,E))T(1T/K)ITN(T,N)ITL(T,L), (2.1)
    dNdt=eCfNp2NT+INT(T,N), (2.2)
    dLdt=(p4LN+p5Iα4+IL)(1L/KL)Tα5+TdL, (2.3)
    dCdt=αβC, (2.4)

    where E(t) is a periodic function and t is in days.

    Tumor growth includes an initial exponential growth phase followed by a linear growth phase. As tumors grow, the availability of resources (nutrients, oxygen, and space) decreases resulting in deceleration of tumor growth, and the tumor size eventually reaches its maximum value [5,37]. The tumor population T is assumed to follow a logistic or sigmoidal curve including three phases: an exponential phase, a linear phase, and a plateau phase. The parameter a is the intrinsic growth rate, and K is the carrying capacity of the tumor.

    The proliferation of MCF-7 cells is known to be stimulated by E2. The term ITE(T,E) represents the interaction between MCF-7 cells and E2. The terms ITN(T,N) and ITL(T,L) represents tumor lysis by NK cells and CTLs, respectively. The term INT(T,N) represents recruitment of NK cells in the presence of tumor cells. Because NK cells are a type of WBCs, the growth of NK cells, eC, depends on the concentration of WBCs. The parameter f represents the death rate of NK cells, and the parameters α and β represent the birth and death rate of WBCs, respectively. NK cells release perforin, which forms pores in the cell membrane of the target cell. They also release granzymes, which enter through these pores, inducing apoptosis. An activated NK cell can kill 4 target cells in 16 hours, and then it appeared to be exhausted due to significant reduction in perforin and granzyme B content [38,39]. The term p2NT, which is adopted from a model of tumor-immune interactions by de Pillis et al. [28], describes that NK cells become inactivated after some encounters with tumor cells, and the parameter p2=3.42×106 represents the mean inactivation rate.

    A normal range for the WBC count is 412×109 cells per liter [40]. Experimental data by [41] have shown that healthy young individuals have NK cell counts of (3.87±1.64)×108 cells/L (Mean±SD) and healthy elderly individuals have NK cell counts of (3.77±2.21)×108 cells/L. It is known that approximately 34% of WBCs are lymphocytes in human blood [42]. Pascal et al. have reported 2 to 31% of NK cells within blood lymphocytes in a group of healthy adults [43]. Thus an immune system with an equilibrium NK cell count of 4×108/L and WBC count of 5.7×109/L is considered to be a normal healthy immune system. The equilibrium concentration of WBC is α/β which is determined by Eq (2.4). The parameter value β=6.3×103 in a research study by de Pillis [44] is used in this paper. An equilibrium WBC concentration of 5.7×109 cells per liter implies α=5.7×109×6.3×103=3.6×107. Experimental data from a research study by Zhang et al. [41] have shown that the half-life of NK cells is about 10 days, and this implies f=0.0693. An equilibrium NK cell count of 4×108/L in the absence of tumor cells implies e=fN/C=0.0693×4×108/5.7×109=0.00486. Consider that the size of an MCF-7 cell is 15-25 μm in diameter [45,46] and a tumor of 2 cm in diameter is within the diagnostic capabilities [47]. Assuming that an MFC-7 cell is 20 μm in diameter, an MCF-7 tumor of 2 cm in diameter contains 109 tumor cells. Several research studies [27,28,48,49,50,51] have also used 109 cells for the carrying capacity K in their mathematical models. In this model, the carrying capacity K=109 is used.

    The matured T cells are considered as naive T cells as they have not encounter appropriate antigen. The number of mature T cells increases progressively during young life and then remains relatively constant during adulthood [52]. An activation of naive CD8+ T cells requires two signals. The first signal occurs when a naive CD8+ T cell encounters and interacts with an antigen presenting cell, such as a dendritic cell and a macrophages, through the T cell receptor (TCR) binding to MHC molecules. The second signal, the co-stimulatory signal, is provided by interaction between CD28 and B7 on the membrane of the T cell and APC, respectively [15]. Once activated, CD8+ T cells undergoes clonal expansion with interleukin-2 (IL-2) stimulation [53]. At the end of immune response, CD8+ T cells undergo a contraction phase during which about 90% of CD8+ T cells die. The cells that survive apoptosis become memory cells for a rapid secondary response to antigen [54].

    The term T/(α5+T) is used to model the phenomenon that CTLs are activated in the presence of tumor cells and undergo apoptosis at the end of immune response. The constant α5 is assumed to be a relatively small number compared with the carrying capacity, K, of tumor cells. In this paper, α5=1000 is assumed. From the clinical data by Gruber et al. [55] in a study of relationship between tumor cells and T lymphocytes in breast cancer patients, the patients had CTL counts of 365±194 cells/μL (Mean±SD) and naive CTL counts of 237±112 cells/μL. The constant LN in Eq (2.3) represents the number of naive CTLs, and LN=2.3×108 cells/L is assumed in this paper. The constant KL represents the carrying capacity of CTLs and KL=8×108 cells/L, which is about mean+2SD, is assumed. Homann et al. [56] have reported that during primary immune response CTLs have a doubling time of 6-10 hours between days 5 and 7 and 24–36 hours between days 7 and 9. The number of CTL population reaches its peak on day 8. De Boer et al. [57] have reported that the half life of CTLs is approximately 41 hours (about 1.7 days) during the contraction phase. This gives a death rate of d=ln2/1.7=0.41 in Eq (2.3). The term p5Iα4+IL represents proliferation of CTLs, where I represents the concentration of IL-2 (g/L). Assume that the average of doubling time during the expansion phase is 8 hours. This gives a growth rate of p5Iα4+I=3ln2=2.07. To estimate the parameter value for p4, assume that T/(α5+T)1 in the presence of tumor during the expansion phase, and the number of CTL population reaches a level at 90% of its carrying capacity KL, which is 7.2×108 on day 8. Equation (2.3) is reduced to

    dLdt=(p4LN+p5Iα4+IL)(1L/KL)dL, (2.5)

    with conditions L(0)=0 and L(8)=7.2×108. Solving for p4 in the above equation gives p4=9×105.

    The interactions between immune cells and tumor cells are usually described by functional responses of the predator-prey type [20]. The typical forms of the predator-prey type are based on Lotka Volterra, Holling type Ⅱ, or Holling type Ⅲ [58]. These forms with predator interference can be sumarised as Ixy(x,y)=ˉpxλ1yλ2/(1+ˉαxλ1+ˉβyλ2). For example, the interaction term Ixy is Lotka Volterra functional response if λ1=λ2=1 and ˉα=ˉβ=0, and Ixy is of Holling type Ⅱ with predator interference if λ1=λ2=1. The functional responses with λ1=1 or 2 and λ2=1 or 2 will be considered in this paper.

    Let Td be the doubling time of the MCF-7 cell population. Then a=ln2/Td. It has been found that the growth of MCF-7 cells in vitro varies over a large range in the absence of estrogens. Experimental data have shown that the population doubling time ranges between 30 hours and several days [59,60,61]. A doubling time of 30 hours is corresponding to a=ln2/(30/24)=0.55 whereas a doubling time of 10 days is corresponding to a=ln2/10=0.069. A value falls in the range 0.069-0.55 is considered a reasonable parameter value for a. MCF-7 cells contain estrogen receptors and are estrogen responsive. Consider the following functional response for ITE(T,E):

    ITE(T,E)=cEλ1Tλ211+α1Eλ1+β1Tλ2. (2.6)

    The parameters λ1=1 or 2, and λ2=1 or 2. Parameters α1 and β1 are positive constants. The MCF-7 growth in the presence of E2 becomes

    dTdt=(a+cEλ1Tλ211+α1Eλ1+β1Tλ2)T(1T/K). (2.7)

    Equation (2.7) is used to fit the experimental data by Nawata et al. [59], where the E2 concentration is 108M. Figure 1 shows the experimental data and the fitting curve. The experimental data show that a population level of 4×106 cells is at the log growth phase. Therefore, K=107 and E2=10000 (pmol/L) are used in this fitting. Let xi, i=0,1,,4 be the number of tumor cells from experimental data shown in Figure 1. The parameters a, c, α1, and β1 are to be found for minimizing 4i=0((Tixi)/xi)2, where Ti=T(3i) is the solution of Eq (2.7) with initial condition T(0)=2×104. Different sets of (λ1,λ2) values are fitted separatedly. The Nelder Mead simplex method is employed to solve the least square error of the fitting. The ODE solver is the Runge Kuta method. The Matlab build-in functions fminsearch and ode45 can also fulfill the tasks. Figure 1 shows that λ1=1 and λ2=2 can best fit Eq (2.7) to the data with the parameter values a=0.3, c=1.93×106, α1=0.507, and β1=7.08×108.

    Figure 1.  Curve fitting for ITE and parameter values a, c, α1, and β1.

    The term ITN(T,N) representing cytolysis of NK cells is modeled as follows:

    ITN(T,N)=p1Tλ1Nλ21+α2Tλ1+β2Nλ2. (2.8)

    Parameter p1, α1, and β1 are positive constants to be determined by experimental data. The interaction between NK cells and tumor cells includes ITN(T,N) and p2NT, where p2=3.42×106. Consider the following equations:

    dTdt=p1Tλ1Nλ21+α2Tλ1+β2Nλ2, (2.9)
    dNdt=p2NT. (2.10)

    The experimental data used in this fitting were provided by Caragine et al. [62], and 4-hour chromium-51 release assays were used in the cytolysis assays. Note that the experiment has been conducted to study MFC-7 tumor cell lysis by NK cells. Figure 2 shows the experimental data and the fitting curve. Let xi, i=0,1,2,3 be the experimental data points in Figure 2 and yi=(T(0)T(4/24))/T(0), where T(4/24) is the solution to Eqs (2.9) and (2.10) with T(0)=106 given in [62] and N(0)=Ni, where N0=0, N1=25T(0), N2=50T(0), and N3=100T(0). The fitting process is formed using different sets of (λ1,λ2). The parameter values for p1, α2, and β2 are to be determined for minimizing 3i=0(yixi)2. It has been found that λ1=1 and λ2=2 can best fit Eqs. (2.9) and (2.10) to the data, with the parameter values p1=8.7×104, α2=7×106, β2=5.4×105.

    Figure 2.  Curve fitting for ITN and parameter values p1, α2, and β2.

    The term ITL(T,L) representing cytolysis by CTLs is modeled as follows:

    ITL(T,L)=p6Tλ1Lλ21+α6Tλ1+β6Lλ2. (2.11)

    The fitting process is similar to that in Section 2.2. Using the experimental data in [63], (λ1,λ2)=(1,1) or (2, 1) can better fit Eq (2.11) to the data than (λ1,λ2)=(1,2). Note that the experiment has been conducted to study MFC-7 tumor cell lysis by CLTs. The parameter values p6=2.36×104, α6=0, β6=6.04×105 are determined for (λ1,λ2)=(1,1) and p6=2.38×108, α6=0, β6=4.3×105 are determined for (λ1,λ2)=(2,1). Figure 3 shows the experimental data and the fitting curve.

    Figure 3.  Curve fitting for ITL and parameter values p6, α6, and β6.

    The term INT(T,N) represents the recruitment of NK cells to the tumor site. To model the recruitment of NK cells, consider the following equations:

    dTdt=aT(1T/K)p1TN21+α2T+β2N2p6T2L1+α6T2+β6L, (2.12)
    dNdt=eCfNp2NT+p3Tλ1Nλ21+α3Tλ1+β3Nλ2, (2.13)
    dLdt=(p4LN+p5Iα4+IL)(1L/KL)Tα5+TdL. (2.14)

    The form and parameter values of the functional response for recruitment of NK cells are to be determined using the experimental data from a research study by Chen et al. [64]. The experiment has been conducted to study and compare different treatment starting after 7 weeks of the presence of MCF-7 breast cancer in ovariectomized nude mice. Therefore, the term ITE is dropped out of Eq (2.12). The experimental data set used in this fitting is the one without treatment. It is assumed that the CTL and NK counts have reached high levels after 7 weeks of the presence of tumor cells, and thus the initial conditions of Eqs (2.12)–(2.14) are given by T(0)=5.7×106, N(0)=2×108, and L(0)=3×108. The proliferation of CTLs slows down to a doubling time of 24–36 hours after reaching the peak level [56]. Using an average doubling time of 30 hours, 1.25 days, gives p5I/(α4+I)=ln2/1.25=0.55 in this fitting. Other experimental data have shown WBC counts of (4.3±0.8)×103 cells/μL in mice [65]. The concentration of WBC is assumed to remain an equilibrium concentration C=4.3×109 cells/L in this fitting. The other parameter values have been determined in the previous subsections. The fitting process is similar to that in Section 2.1, where p3, α3, and β3 are unknown parameters. Figure 4 shows the experimental data and the fitting curve for all sets of (λ1,λ2) values.

    Figure 4.  Parameter values determined for p6, α6, and β6 in Section 2.3 poorly fit the data.

    Figure 4 also shows that the model, Eqs (2.12)–(2.14), with the parameter values determined in the previous subsections gives strong cytotoxic function that cannot well fit the in vivo data. The fitting process is repeated using (λ1,λ2)=(1,1) and unknown parameters p3, α3, β3, p6, α6, and β6. It has been found that the result of the fitting is satisfactory, Figure 5 shows the experimental data and the fitting curve, and the parameter values p3=1.87×108, α3=1.6×105, β3=3.27, p6=2.04×103, α6=0.268×106, and β6=4343 are determined.

    Figure 5.  Curve fitting for INT and parameter values p3, α3, β3, p6, α6, and β6.

    Finally, the blood content of estradiol provided by Wu et al. [66] is used for the periodical function E(t). Let τ=29 be the period of E(t), and ˜E(t), t[0,τ) be the function whose graph is shown in Figure 6. Then E(t)=˜E(tnτ) for t[nτ,(n+1)τ).

    Figure 6.  Estradiol levels across the menstrual cycle.

    Using the specific forms for Eqs (2.1)–(2.4) leads to the following equations:

    dTdt=T(a+cET1+α1E+β1T2)(1T/K)p1TN21+α2T+β2N2 (2.15)
    p6T2L1+α6T2+β6L, (2.16)
    dNdt=eCfNp2NT+p3NT1+α3T+β3N, (2.17)
    dLdt=(p4LN+p5Iα4+IL)(1L/KL)Tα5+TdL, (2.18)
    dCdt=αβC, (2.19)
    E(t)=˜E(tnτ),t[nτ,(n+1)τ). (2.20)

    A simulation study by Nikolopoulou et al. [67] have reported that the IL-2 density is not very dynamic and the equilibrium density of IL-2 is about 2.37×108g/L which is also the value for half saturation constant α4. This assumption gives p5=4.14 since p5Iα4+I=2.07. The parameter values are summarized and shown in Table 1.

    Table 1.  Parameter values in Eqs (2.16)–(2.20).
    Parameter Value Units Reference
    a 0.3 Day1 fitted with data [59]
    c 1.93×106 L Cell1 Day1 pmol1 fitted with data [59]
    α1 0.507 L pmol1 fitted with data [59]
    β1 7.08×108 Cell1 fitted with data [59]
    K 109 Cell [27,28,48,49,50,51]
    p1 8.7×104 L2 Cell2 Day1 fitted with data [62]
    α2 7×106 Cell1 fitted with data [62]
    β2 5.4×105 L2 Cell2 fitted with data [62]
    β 6.3×103 Day1 [44]
    α 3.6×107 Cell L1 Day1 Estimated within bounds [40]
    e 0.00486 Day1 Estimated within bounds [41]
    f 0.0693 Day1 Estimated from data [41]
    p2 3.42×106 Cell Day1 [28,100]
    p3 1.87×108 Cell 1 Day1 fitted with data [62]
    α3 1.6×105 Cell1 fitted with data [62]
    β3 3.27 L Cell1 fitted with data [62]
    p6 2.04×103 L Cell2 Day1 fitted with data [62]
    α6 0.268 Cell2 fitted with data [62]
    β6 4343 L Cell1 fitted with data [62]
    LN 2.3×108 Cell L1 Estimated from data [55]
    KL 8×108 Cell L1 Estimated from data [55]
    p4 9×105 Day1 Estimated from data [56,55]
    I 2.3×1011 g L1 [67,107]
    α4 2.3×1011 g L1 [67,107]
    p5 4.14×103 L Cell2 Day1 Estimated from data [56]
    d 0.41 Day1 Estimated from data [57]
    α5 1000 Cell Assumed

     | Show Table
    DownLoad: CSV

    In this section, the dynamics of the model, Eqs (2.16)–(2.20), with parameter values shown in Table 1 are to be studied. For the tumor free case, Eqs (2.16)–(2.20) with parameter values shown in Table 1 give that an immune system has equilibrium levels of NK cell population and WBC population are 4×108 cells/L and 5.7×109 cells/L, respectively.

    Vacca et al. have reported that the immune system is able to eliminate tumors at initial stages [68], and it has been demonstrated that most tumor cells entering the circulation are destroyed during the first 24 hours [69,70,71]. In the first numerical experiment, an initial tumor burden of 106 cells, T(0)=106, is considered. In this case, it is assumed that the tumor has escaped immune surveillance and grown to reach a population level of 106 cells. Note that a tumor of 106 cells has a size about 2 mm in diameter and is clinically undetectable. Furthermore, assume that this is the first immune response against the cancer so no effector CTL is present initially. That is L(0)=0. While the activation of CTLs requires some time, Figure 7(a) shows that NK cells provide the first line of defense against cancer and are able to quickly eliminate the tumor.

    Figure 7.  A healthy normal immune system using parameter values listed in Table 1 with initial conditions (a) (T(0),N(0),C(0),L(0))=(106,4×108,4×109,0) and (b) (T(0),N(0),C(0),L(0))=(2×106,4×108,4×109,0), (c) (T(0),N(0),C(0),L(0))=(4×106,4×108,4×109,0), and (d) (T(0),N(0),C(0),L(0))=(2×106,4×108,4×109,4×107).

    Suppose that the immune system fails to become activated against a tumor so the tumor grows to a population level of 2×106 cells. A tumor of 2×106 cells has a size of less than 3 mm in diameter. Figure 7(b) shows that a healthy immune system is able to control but not able to completely eliminate this tumor. The size of the tumor decreases to a population level of about 6×105 cells and has a size of less than 2 mm in diameter. Then the tumor remains small and stable. Evidence suggests that many microscopic tumors never progress to become invasive, a phenomenon termed "cancer without disease" [16,17,18,72]. At this stage, a balance between immune response and tumor growth could result in long-term persistence of tumor dormancy. Figure 7(c) shows that a healthy immune system is not able to control a tumor of 4×106 cells, which has a size of 3.2 mm in diameter. The tumor grows to its carrying capacity eventually. The NK cell population remains at a low population level after the tumor reaches its carrying capacity.

    Clinical and experimental observations have demonstrated the existence of immunosurveillance process that can destroy cancer cells or prevent primary tumor growth. The cancer immunoediting hypothesis has been developed based on these findings. Cancer immunoediting, which describes the relation between the tumor cells and the immune system, is composed of elimination, equilibrium, and escape phases [73,74]. Elimination is refered to as classical concept of immunosurveillance. Equilibrium occurs when the immune system fails to completely eliminate the tumor but is able to control the tumor leading to long term dormancy. Escape refers to the tumor outgrowth. Figs. 7(a)-(c) show that the system has three locally stable equilibria: the tumor free equilibrium, the equilibrium representing a microscopic tumor, and the equilibrium representing a large tumor.

    During the contraction phase, 5-10% of CTLs differentiate into memory T cells [56]. Memory T cells can be immediately activated and trigger the second immune response when the individual is exposed to the same pathogen the next time. Figs. 7(b) and (c) shows that the CTL population reaches a high level of 6.4×108 cells/L after the expansion phase. Assume T(0)=4×107 which is about 6% of the CTL population at the peak level. Figure 7(d) shows that the second immune response is able to eliminate a tumor of 2×106 cells which is larger than the tumor that an immune system can eliminate in the first response. A tumor of 4×106 cells grows to its carrying capacity during the second response (the graph is not shown). Note that although the solutions shown in Figs. 7(a)-(c) appear to approach equilibria, these solutions oscillate with very small amplitudes since E(t) is periodic. These periodic solutions are referred to as equilibria throughout the paper for convenience because their oscillation amplitudes are too small to be seen.

    Recall that the parameter values fitted to the in vitro data, Figure 3, gives relatively strong cytotoxicity of CTLs against tumor cells compared to the in vivo data. Tumors may secrete molecules that weaken and inhibit CTL functions [75] or express molecules that directly inhibit the killing ability of CTLs such as immune checkpoint molecules CD80 or PD-L1 [76]. Adoptive cell transfer (ACT) therapy can produce highly active CTLs which give strong immune response [77]. Immune checkpoint therapy using checkpoint inhibitor antibodies, such as anti PD-1, anti PD-L1, or anti CTLA-4, can overcome tumor-induced immune dysfunction and enhance immune response against cancer [78].

    The parameter p6, which is related to the killing activity of CTLs, can be used as an indicator of the strength of cytotoxicity of CTLs. Let p6=4×103 which is twice the cytotoxic strength used in Section 3.1. Figure 8(a) shows that the immune system is able to eliminate a tumor of 4×106 cells. When the immune system detects the presence of the tumor, the NK cells fight against the tumor cells during the activation phase, where CTLs are at a low population level. The tumor continues to grow during the activation and expansion phases. After the expansion phase, CTLs are able to control the growth of the tumor and then eliminate the tumor. It is followed by a contraction phase at the end of the immune response. Figure 8(b) shows this immune system is able to eliminate a tumor of 3×107 cells, which has a size of 6 mm in diameter, when p6=2.04×102. The population level of NK cells decreases initially when the immune system is fighting against the tumor. After the tumor has been killed, the immune system starts to recover and strengthen.

    Figure 8.  A immune system parameter values listed in Table 1 and different p6 values and initial conditions, (a) p6=4×103 and (T(0),N(0),C(0),L(0))=(4×106,4×108,4×109,0) and (b) p6=2.04×102 and (T(0),N(0),C(0),L(0))=(3×107,4×108,4×109,0).

    The dynamical system, Eqs (2.16)–(2.20), with parameter values listed in Table 1 exhibits multistability. The asymptotic behavior of a solution depends on its initial conditions, which are the initial level of tumor cell population T(0), the initial NK cell count N(0), the initial NK cell count N(0), and the initial WBC count, C(0). Lymphopenia is the condition of having an abnormally low lymphocyte count in the bloodstream. Ebbo et al. [79] have studied the impact of low circulating NK cell counts and found a correlation between NK cell lymphopenia and invasive bacterial infections. Patients with severe NK cell lymphopenia have higher incidence of invasive bacterial infections. Although the experimental data in their study have shown negative association between cancer risk and the NK cell count, the correlation is not significant.

    An individual with severe or mild NK cell lymphopenia has an NK cell count of <5×107cells/L or 59×107cells/L, respectively [79]. In a cohort of 457 common variable immunodeficiency patients, 21.7% of the patients have severe NK cell lymphopenia, 25.8% of the patients have mild NK cell lymphopenia, and 52.5% of the patients have normal NK cell counts. In a cohort of 145 healthy adults, 5% of theses healthy controls have NK cell counts below 63×106 NK cells/L (Figure S1 of [79]) indicating that a healthy individual may have severe NK cell lymphopenia. Suppose that a low NK cell count is temporary. The case of persistent lymphopenia will be discussed in the next subsection. Figure 9(a) shows that an individual with mild NK cell lymphopenia, where N(0)=8×107, can rapidly eliminate a tumor of 2×105 cells, which has a size of 1 mm in diameter. Figure 9(b) shows that the immune system is able to control a tumor of 106 cells but is not able to completely eliminate the tumor which a heathy immune system can effectively eliminate.

    Figure 9.  Immune systems with NK lymphopenia using parameter values listed in Table 1 with initial conditions (a) (T(0),N(0),C(0),L(0))=(2×105,8×107,4×109,0), (b) (T(0),N(0),C(0),L(0))=(106,8×107,4×109,0), and (c) (T(0),N(0),C(0),L(0))=(2×105,2×107,4×109,0).

    When an individual suffers from severe NK cell lymphopenia, where N(0)=2×107, Figure 9(c) show that the immune system is able to eliminate a tumor of 1 mm in diameter after the CTL population is expanded. Figure 9(a)(c) show that an individual with severe or mild NK cell lymphopenia can eliminate a tumor of 2×105 cells but is not able to completely eliminate a tumor of 106 cells which a heathy immune system can effectively eliminate.

    Low WBC counts weaken the immune system and increase the risk of bacteria and virus infection. Some studies have suggested correlation between WBC count and coronary heart disease, stroke, and cancer mortality [80,81,82]. Other studies have reported that impact of the WBC count on cardiovascular disease is inconsistent [83,84]. Clinical studies have found that a weakened immune system may increase risk of new cases of cancer in immunocompromised populations [11,85,86,87]. Jee et al. [80] have shown that patients with WBC counts of <5×109 have higher cancer mortality than patients with WBC counts of 58×109 do. Nevertheless Kim et al. [11] have reported that the association between cancer risk and WBC count is inconsistent.

    Conditions, such as infectious diseases, chemotherapy, drugs, anemia, splenic dysplasia, birth disorders, or damaging the bone marrow can lead to a low WBC count [88]. In this subsection, a system with an eqilibrium WBC count and an eqilibrium NK cell count lower than the normal ranges is considered. The parameter α is related to the production rate of while blood cells. A lower production rate of WBCs corresponds to a smaller α value. An individual with α=1.575×107 has an equilibrium WBC count of α/β=2.5×109, where clinical studies consider 2.5×109 cells/L as a low WBC count [89,90,91,92]. Let e=8.32×104, and the equilibrium NK cell count in the absence of a tumor becomes 5×107 cells/L which is lower than the normal values. Furthermore, let p4=3×105 indicating a lower activation in CTL immune response. All other parameter values are listed in Table 1. Figure 10 shows the ability of an immune system, with a low WBC count and a low NK cell count, to fight a cancer. The immune system is able to effectively eliminate a tumor of 2×105 cells as shown in Figure 10(a). Figure 10(b) shows that the immune system is able to control a tumor with an initial population level of 106 cells, and Figure 10(c) shows that a tumor with an initial population level of 2×106 cells will eventually grow to its carrying capacity.

    Figure 10.  A weakened immune system using parameter values α=1.575×107, e=8.32×104, p4=3×105, and all other parameter values listed in Table 1 with initial conditions (a) (T(0),N(0),C(0),T(0),L(0))=(2×105,5×107,4×109,0), (b) (T(0),N(0),C(0),L(0))=(106,5×107,2.5×109,0), and (c) (T(0),N(0),C(0),L(0))=(2×106,5×107,2.5×109,0).

    Experimental and clinical data support that circulating estradiol is positively associated with breast cancer risk in postmenopausal women [93,94,95,96]. However, in premenopausal women, most prospective studies found no significant association between breast cancer risk and estrogens [96,97,98,99]. The numerical simulation using parameter values in Table 1 with a 10-fold increase in the circulating estradiol level shows that the immune system is able to effectively eliminate a tumor of 106 cells and control a tumor of 2×106 cells. A tumor of 4×106 cells grows to its carrying capacity. In the case of a 100-fold increase in the circulating estradiol level, the numerical simulation shows that the immune response against cancer is similar to the case of a 10-fold increase. Figures of numerical simulation in this subsection are not shown because the figures resemble those that appear in the previous subsections. The numerical results suggest that an increase in the circulating estradiol level does not show a significant increase in cancer risk.

    A review of previously published mathematical models of tumor-immune interactions [20] has pointed out that most of these studies present the results derived from mathematical models and very few experimental or clinical results have been compared with these results obtained with mathematical models. Moreover, many of these models have not considered a specific cancer type or justified the functional forms using clinical or experimental data. In this paper, a mathematical model for the growth of breast tumors of MCF-7 cell line is constructed. All the parameter values (except for p2, β, and α5) as well as the forms of functional responses for the effect of estradiol, tumor lysis by NK cells, and recruitment for NK cells have been estimated using experimental data [40,41,45,46,55,56,57,59,60,61,62,63,64,66]. The parameter values for the mean inactivation rate for NK cells p2 and the death rate of WBCs β can be found in the study by de Pillis et al. [28,44,100]. The results of the fitting procedures are shown in Figures 16.

    Numerical simulation shows that a healthy normal immune system exhibits multistability where the tumor free, microscopic tumor, and large tumor equilibria are stable. The phenomena resemble the 3 E's of cancer immunoediting [73,74]. The immune system is able to rapidly eliminate a tumor with a restricted initial size and the critical size of a tumor that the immune system can eliminate is about 2 mm in diameter (Figure 7). Several experimental studies have demonstrated that NK cells can rapidly eliminate a tumor at initial stages [68,101,102,103]. A healthy normal immune system may also produce long-term dormancy (Figure 7(b)). The tumor does not grow to become large or lethal and remains at an equilibrium size of less than 2 mm in diameter. This phenomenon has been widely observed in clinical studies [16,17,18,72]. Clinical and experimental studies have suggested that an immune system may increase its antitumor effect by enhancing the cytotoxicity of CTLs using ACT therapy, tumor vaccines, or checkpoint antibodies [104,105,106]. Numerical simulation shows that an immune system with a stronger killing activity, a larger p6 value, can eliminate a larger tumor (Figure 8).

    An individual suffering from temporary NK cell lymphopenia has a low NK cell count. Numerical simulation demonstrates that there is a positive association between the size of a tumor which an immune system is able to effectively eliminate and the initial NK cell count. Although an immune system with NK cell lymphopenia is not able to effectively eliminate a tumor that a healthy normal immune system is able to (Figure 7(b)), it can rapidly eliminate a smaller tumor (Figure 9(a)). This also suggests that a lower NK cell count may increase cancer risk but the relationship is not significant. Clinical data [79] have shown a similar result that the group with lower NK cell counts has higher tumor incidence rate but the association is not significant.

    Immune system strength is important in determining whether or not an immune system is able to eliminate a small tumor. Leukopenia, a low WBC count, is associated with several clinical disorders [88]. Numerical simulation shows that a weakened immune system with persistently low NK cell and WBC counts and a slower activation of CTL immune response may fail to control the growth of a tumor which a healthy immune system is able to control (Figures 7(b) and 10(c)). Finally, numerical simulation also shows that the effect of the estradiol concentration E2 on formation of a tumor is not significant which agrees with observations by previous research studies [96,97,98,99].

    This research work was supported by the Ministry of Science and Technology under the grant MOST107-2115-M-035-006.

    The author declare there is no conflict of interest.



    [1] PCBS (2021, May 26). Estimated Population in the Palestine Mid-Year by Governorate, 1997-2026. Palestinian Central Bureau of Statistics. Retrieved November 19, 2021, Available from: https://www.pcbs.gov.ps/statisticsIndicatorsTables.aspx?lang=en&table_id=676.
    [2] (PENRA), P.E.a.N.R.A. Paving the Way for a Renewable Energy Future in Palestine. Available from: http://www.penra.pna.ps/ar/Uploads/Files/Electric%20power%20in%20Palestine%202016-2019.pdf.
    [3] Khatib T, Bazyan A, Assi H, et al. (2021) Palestine energy policy for photovoltaic generation: Current status and what should be next? Sustainability 13: 2996. https://doi.org/10.3390/su13052996 doi: 10.3390/su13052996
    [4] Sukarno K, Hamid ASA, Razali H, et al. (2017) Evaluation on cooling effect on solar PV power output using Laminar H2O surface method. Int J Renewable Energy Res 7: 1213-1218.
    [5] Ahmad EZ, Sopian K, Jarimi H, et al. (2021) Recent advances in passive cooling methods for photovoltaic performance enhancement. Int J Electr Comput Eng 11: 146. https://doi.org/10.11591/ijece.v11i1.pp146-154 doi: 10.11591/ijece.v11i1.pp146-154
    [6] Ueda Y, Kurokawa K, Kitamura K, et al. (2009) Performance analysis of various system configurations on grid-connected residential PV systems. Sol Energy Mater Sol Cells 93: 945-949. https://doi.org/10.1016/j.solmat.2008.11.021 doi: 10.1016/j.solmat.2008.11.021
    [7] Monna S, Juaidi A, Abdallah R, et al. (2020) A comparative assessment for the potential energy production from PV installation on residential buildings. Sustainability 12: 10344. https://doi.org/10.3390/su122410344 doi: 10.3390/su122410344
    [8] Sugiura T, Yamada T, Nakamura H, et al. (2003) Measurements, analyses and evaluation of residential PV systems by Japanese monitoring program. Sol Energy Mater Sol Cells 75: 767-779. https://doi.org/10.1016/S0927-0248(02)00132-0 doi: 10.1016/S0927-0248(02)00132-0
    [9] Baran ME, Hooshyar H, Shen Z, et al. (2011) Impact of high penetration residential PV systems on distribution systems. In Proceedings of the 2011 IEEE Power and Energy Society General Meeting, IEEE, 1-5. https://doi.org/10.1109/PES.2011.6039799
    [10] Leloux J, Narvarte L, Trebosc D (2012) Review of the performance of residential PV systems in France. Renewable Sustainable Energy Rev 16: 1369-1376. https://doi.org/10.1016/j.rser.2011.10.018 doi: 10.1016/j.rser.2011.10.018
    [11] Omar MA, Mahmoud MM (2018) Grid connected PV-home systems in Palestine: A review on technical performance, effects and economic feasibility. Renewable Sustainable Energy Rev 82: 2490-2497. https://doi.org/10.1016/j.rser.2017.09.008 doi: 10.1016/j.rser.2017.09.008
    [12] Weniger J, Tjaden T, Quaschning V (2014) Sizing of residential PV battery systems. Energy Procedia 46: 78-87. https://doi.org/10.1016/j.egypro.2014.01.160 doi: 10.1016/j.egypro.2014.01.160
    [13] Watts D, Valdés MF, Jara D, et al. (2015) Potential residential PV development in Chile: The effect of Net Metering and Net Billing schemes for grid-connected PV systems. Renewable Sustainable Energy Rev 41: 1037-1051. https://doi.org/10.1016/j.rser.2014.07.201 doi: 10.1016/j.rser.2014.07.201
    [14] Amuzuvi CK (2014) Design of a photovoltaic system as an alternative source of electrical energy for powering the lighting circuits for premises in Ghana. J Electr Electron Eng 2: 9. https://doi.org/10.11648/j.jeee.20140201.12 doi: 10.11648/j.jeee.20140201.12
    [15] Camilo FM, Castro R, Almeida ME, et al. (2017) Economic assessment of residential PV systems with self-consumption and storage in Portugal. Sol Energy 150: 353-362. https://doi.org/10.1016/j.solener.2017.04.062 doi: 10.1016/j.solener.2017.04.062
    [16] Guo L, Cheng Y, Zhang L, et al. (2008) Research on power—factor regulating tariff standard. International Conference on Electricity Distribution. In Proceedings of the IEEE, China.
    [17] Kawasaki S, Kanemoto N, Taoka H, et al. (2012) Cooperative voltagecontrol method by power factor control of PV systems and LRT. IEEJ Trans Power Energy 132: 309-316. https://doi.org/10.1541/ieejpes.132.309 doi: 10.1541/ieejpes.132.309
    [18] Malengret M, Gaunt CT (2020) Active currents, power factor, and apparent power for practical power delivery systems. IEEE Access 8: 133095-133113. https://doi.org/10.1109/ACCESS.2020.3010638 doi: 10.1109/ACCESS.2020.3010638
    [19] Emmanuel M, Rayudu R, Welch I (2017) Impacts of power factor control schemes in time series power flow analysis for centralized PV plants using Wavelet Variability Model. IEEE Trans Ind Informatics 13: 3185-3194. https://doi.org/10.1109/TⅡ.2017.2702183 doi: 10.1109/TⅡ.2017.2702183
    [20] Peng W, Baghzouz Y, Haddad S (2013) Local load power factor correction by grid-interactive PV inverters. In Proceedings of the 2013 IEEE Grenoble Conference; IEEE, 1-6. https://doi.org/10.1109/PTC.2013.6652412
    [21] Gusman LS, Pereira HA, Callegari JMS, et al. (2020) Design for reliability of multifunctional PV inverters used in industrial power factor regulation. Int J Electr Power Energy Syst 119: 105932. https://doi.org/10.1016/j.ijepes.2020.105932 doi: 10.1016/j.ijepes.2020.105932
    [22] Hassaine L, Olias E, Quintero J, et al. (2009) Digital power factor control and reactive power regulation for grid-connected photovoltaic inverter. Renewable Energy 34: 315-321. https://doi.org/10.1016/j.renene.2008.03.016 doi: 10.1016/j.renene.2008.03.016
    [23] Rani PS (2020) Enhancement of power quality in grid connected PV system. Indian J Sci Technol 13: 3630-3641. https://doi.org/10.17485/IJST/v13i35.1266 doi: 10.17485/IJST/v13i35.1266
    [24] Aziz A, Purwar V (2017) Simulation of high power factor single phase inverter for PV solar array : A survey. 0869: 174-177.
    [25] Solutions, GSE, Power Factor and Grid-Connected Photovoltaics. 2015. Available from: https://www.gses.com.au/wp-content/uploads/2016/03/GSES_powerfactor-110316.pdf.
    [26] Electric S. How to avoid power factor degradation due to the integration of solar production? Available from: https://www.electrical-installation.org/enwiki/Power_factor_-_impact_of_solar_self-consumption.
    [27] Power L. Understanding the effects of introducing solar PV and how it can affect "Power Factor" on complex Industrial/Commercial sites; Available from: https://www.livingpower.com.au/power-factor.
    [28] NEDCO. PV Net Metering System Instructions. Available from: http://www.nedco.ps/?ID=1536.
    [29] JDECO. PV Plants Building Instructions. Available from: https://www.jdeco.net/ar_folder.aspx?id=FWg0CFa23793825aFWg0CF.
    [30] Magazine P (2019) Palestine to bring online its first PV plant, at 7.5 MW. Available from: https://www.pv-magazine.com/2019/05/24/palestine-to-bring-online-its-first-pv-plant-at-7-5-mw/.
    [31] Authority, P.E.a.N.R. Energy Policy Articles 2020; Available from: http://www.penra.pna.ps/ar/index.php?p=penra6.
    [32] Bullich-massagu E, Ferrer-san-jos R, Serrano-salamanca L, Pacheco-navas, C.; Gomis-bellmunt, O. PowerPlantControl. Available from: http://dx.doi.org/10.1049/iet-rpg.2015.0113.
    [33] Bernáth F, Mastný P. Power Factor Compensation of Photovoltaic Power Plant. 2012, 0-4. Available from: https://core.ac.uk/download/pdf/295548557.pdf.
    [34] University, B. Birzeit University and Qudra inaugurate a 1 megawatt solar power plant. 2021; Available from: https://www.birzeit.edu/en/node/45562.
    [35] Solutions, Q.f.R.E. Qudra for Renewable Energy Solutions begins operating a 1 megawatt solar power plant for the Yabad Electricity Authority. 2021. Available from: https://www.wattan.net/ar/news/336254.html.
    [36] Daud MZ, Mohamed A, Che Wanik MZ, et al. (2012) Performance evaluation of Grid-Connected photovoltaic system with battery energy storage. IEEE International Conference on Power and Energy (PECon). https://doi.org/10.1109/PECon.2012.6450234
    [37] Assadeg J, Sopian K, Fudholi A (2019) Performance of grid-connected solar photovoltaic power plants in the Middle East and North Africa. Int J Electr Comput Eng (IJECE) 9: 3375. https://doi.org/10.11591/ijece.v9i5.pp3375-3383 doi: 10.11591/ijece.v9i5.pp3375-3383
    [38] Farhoodnea M, Mohamed A, Khatib T, et al. (2015) Performance evaluation and characterization of a 3-kWp grid-connected photovoltaic system based on tropical field experimental results: new results and comparative study. Renewable Sustainable Energy Rev 42: 1047-1054. https://doi.org/10.1016/j.rser.2014.10.090 doi: 10.1016/j.rser.2014.10.090
    [39] Kamaruzzaman Z, Mohamed A, Shareef H (2015) Effect of grid-connected photovoltaic systems on static and dynamic voltage stability with analysis techniques—a review. PRZEGLĄD ELEKTROTECHNICZNY 1: 136-140. https://doi.org/10.15199/48.2015.06.27 doi: 10.15199/48.2015.06.27
    [40] Farhoodnea M, Mohamed A, Shareef H, et al. (2013) Power quality analysis of Grid-Connected photovoltaic systems in distribution networks. PRZEGLĄD ELEKTROTECHNICZNY. https://doi.org/10.1109/SCOReD.2012.6518600
  • This article has been cited by:

    1. Ateq Alsaadi, Advancing water quality management: A synergistic approach using fractional differential equations and neural networks, 2025, 10, 2473-6988, 5332, 10.3934/math.2025246
    2. Ayesha Saleem, Mati ur Rahman, Salah Boulaaras, Rafik Guefaifia, Dumitru Baleanu, Exploring the dynamics of HIV and HCV co-infection through piecewise modified Mittag-Leffler fractional derivatives, 2025, 33, 2769-0911, 10.1080/27690911.2025.2478038
  • Reader Comments
  • © 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(13226) PDF downloads(614) Cited by(3)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog